About Regeneron Pharmaceuticals, Inc.
Regeneron earns most revenue from Dupixent (immunology blockbuster, $14B+ global sales) and Eylea (ophthalmology). Low beta (~0.4) despite biotech classification — driven by high-margin recurring drug sales. Pays a token ~0.5% dividend; moderate IV with periodic spikes around FDA decisions and earnings.
Biotechnology